MABVAX THERAPEUTICS HOLDINGS, INC. - FORM 10-K - EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - March 1, 2017

Attached files

file filename
EX-32.2 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - MABVAX THERAPEUTICS HOLDINGS, INC.ex32-2.htm
EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - MABVAX THERAPEUTICS HOLDINGS, INC.ex32-1.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - MABVAX THERAPEUTICS HOLDINGS, INC.ex31-2.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - MABVAX THERAPEUTICS HOLDINGS, INC.ex31-1.htm
10-K - FORM 10-K - MABVAX THERAPEUTICS HOLDINGS, INC.mbvx10k_dec312016.htm
 
Exhibit 23.1
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
We consent to the incorporation by reference in the registration statements on Form S-8 (No. 333-203200) of MabVax Therapeutics Holdings, Inc., of our report dated March 1, 2017, related to our audit of the consolidated financial statements of MabVax Therapeutics Holdings, Inc., as of December 31, 2016 and 2015 and for the years then ended, which report included an explanatory paragraph relating to MabVax Therapeutics, Inc.’s ability to continue as a going concern, included in this 2016 Annual Report on Form 10-K.
 
/s/ CohnReznick LLP
 
San Diego, California
March 1, 2017
 
 
 
 
 

Stock widget

Investing forum

MABVAX THERAPEUTICS HOLDINGS, INC. Reports